Zobrazeno 1 - 10 of 43 pro vyhledávání: '"Kooijman JJ"'
1
Akademický článek
Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor.
Autor: Jang S; Elevar Therapeutics, Fort Lee, NJ, USA. sjang@elevartherapeutics.com., Strickland B; Elevar Therapeutics, Fort Lee, NJ, USA., Finis L; Elevar Therapeutics, Fort Lee, NJ, USA., Kooijman JJ; Oncolines B.V., Oss, The Netherlands., Melis JJTM; Oncolines B.V., Oss, The Netherlands., Zaman GJR; Oncolines B.V., Oss, The Netherlands., Van Tornout J; Elevar Therapeutics, Fort Lee, NJ, USA.
Publikováno v: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2023 Jun; Vol. 91 (6), pp. 491-499. Date of Electronic Publication: 2023 May 06.
Zobrazit plný text záznamu
2
Akademický článek
Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines.
Autor: Nishiguchi G; Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA., Mascibroda LG; Department of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA., Young SM; Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA., Caine EA; Promega Corporation, 5430 East Cheryl Drive, Madison, WI, 53711, USA., Abdelhamed S; Department of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA., Kooijman JJ; Oncolines B.V., Kloosterstraat 9, 5349 AB, Oss, The Netherlands., Miller DJ; Department of Structural Biology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA., Das S; Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA., McGowan K; Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA., Mayasundari A; Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA., Shi Z; Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA., Barajas JM; Department of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA., Hiltenbrand R; Department of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA., Aggarwal A; Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA., Chang Y; Department of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA., Mishra V; Department of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA., Narina S; Center for Advanced Genome Engineering, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA., Thomas M; Department of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA., Loughran AJ; Center for Advanced Genome Engineering, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA., Kalathur R; Department of Structural Biology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA., Yu K; Center for Proteomics and Metabolomics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA., Zhou S; Center for Proteomics and Metabolomics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA., Wang X; Center for Proteomics and Metabolomics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA., High AA; Center for Proteomics and Metabolomics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA., Peng J; Department of Structural Biology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA.; Center for Proteomics and Metabolomics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA., Pruett-Miller SM; Center for Advanced Genome Engineering, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA.; Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, Memphis, TN, 38105, USA., Daniels DL; Promega Corporation, 5430 East Cheryl Drive, Madison, WI, 53711, USA., Urh M; Promega Corporation, 5430 East Cheryl Drive, Madison, WI, 53711, USA., Shelat AA; Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA., Mullighan CG; Department of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA., Riching KM; Promega Corporation, 5430 East Cheryl Drive, Madison, WI, 53711, USA., Zaman GJR; Oncolines B.V., Kloosterstraat 9, 5349 AB, Oss, The Netherlands., Fischer M; Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA. marcus.fischer@stjude.org., Klco JM; Department of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA. jeffery.klco@stjude.org., Rankovic Z; Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA. zoran.rankovic@stjude.org.
Publikováno v: Nature communications [Nat Commun] 2024 Jan 16; Vol. 15 (1), pp. 482. Date of Electronic Publication: 2024 Jan 16.
Zobrazit plný text záznamu
3
Akademický článek
Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020.
Autor: Kooijman JJ; Oncolines B.V., Oss, Netherlands., van Riel WE; Oncolines B.V., Oss, Netherlands., Dylus J; Oncolines B.V., Oss, Netherlands., Prinsen MBW; Netherlands Translational Research Center B.V., Oss, Netherlands., Grobben Y; Oncolines B.V., Oss, Netherlands., de Bitter TJJ; Oncolines B.V., Oss, Netherlands., van Doornmalen AM; Oncolines B.V., Oss, Netherlands., Melis JJTM; Oncolines B.V., Oss, Netherlands., Uitdehaag JCM; Netherlands Translational Research Center B.V., Oss, Netherlands., Narumi Y; Carna Biosciences, Inc., Kobe, Japan., Kawase Y; Carna Biosciences, Inc., Kobe, Japan., de Roos JADM; Oncolines B.V., Oss, Netherlands., Willemsen-Seegers N; Oncolines B.V., Oss, Netherlands., Zaman GJR; Oncolines B.V., Oss, Netherlands.
Publikováno v: Frontiers in oncology [Front Oncol] 2022 Sep 14; Vol. 12, pp. 953013. Date of Electronic Publication: 2022 Sep 14 (Print Publication: 2022).
Zobrazit plný text záznamu
4
Akademický článek
Multi-omics analyses of MEN1 missense mutations identify disruption of menin-MLL and menin-JunD interactions as critical requirements for molecular pathogenicity.
Autor: Dreijerink KMA; Department of Endocrinology, Amsterdam UMC, Amsterdam, The Netherlands., Ozyerli-Goknar E; German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Urology, Medical Center -University of Freiburg, Freiburg, Germany., Koidl S; German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Urology, Medical Center -University of Freiburg, Freiburg, Germany., van der Lelij EJ; Department of Endocrinology, Amsterdam UMC, Amsterdam, The Netherlands., van den Heuvel P; School of Life Sciences, and Research Group of Technologies of Analyses in Life Sciences (ATLS), Avans University of Applied Sciences, Breda, The Netherlands., Kooijman JJ; School of Life Sciences, and Research Group of Technologies of Analyses in Life Sciences (ATLS), Avans University of Applied Sciences, Breda, The Netherlands.; Oncolines B.V., Oss, The Netherlands., Biniossek ML; Institute for Molecular Medicine and Cell Research, University of Freiburg, Freiburg, Germany., Rodenburg KW; School of Life Sciences, and Research Group of Technologies of Analyses in Life Sciences (ATLS), Avans University of Applied Sciences, Breda, The Netherlands., Nizamuddin S; German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Urology, Medical Center -University of Freiburg, Freiburg, Germany., Timmers HTM; German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), Heidelberg, Germany. m.timmers@dkfz-heidelberg.de.; Department of Urology, Medical Center -University of Freiburg, Freiburg, Germany. m.timmers@dkfz-heidelberg.de.
Publikováno v: Epigenetics & chromatin [Epigenetics Chromatin] 2022 Aug 09; Vol. 15 (1), pp. 29. Date of Electronic Publication: 2022 Aug 09.
Zobrazit plný text záznamu
5
Akademický článek
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors.
Autor: Conlon NT; National Institute of Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland. neil.conlon@dcu.ie., Kooijman JJ; Netherlands Translational Research Center B.V., Kloosterstraat 9, 5349 AB, Oss, The Netherlands., van Gerwen SJC; Netherlands Translational Research Center B.V., Kloosterstraat 9, 5349 AB, Oss, The Netherlands., Mulder WR; Netherlands Translational Research Center B.V., Kloosterstraat 9, 5349 AB, Oss, The Netherlands., Zaman GJR; Netherlands Translational Research Center B.V., Kloosterstraat 9, 5349 AB, Oss, The Netherlands., Diala I; Puma Biotechnology, Inc., 10880 Wilshire Boulevard, Suite 2150, Los Angeles, CA, 90024, USA., Eli LD; Puma Biotechnology, Inc., 10880 Wilshire Boulevard, Suite 2150, Los Angeles, CA, 90024, USA., Lalani AS; Puma Biotechnology, Inc., 10880 Wilshire Boulevard, Suite 2150, Los Angeles, CA, 90024, USA., Crown J; National Institute of Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland.; Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland., Collins DM; National Institute of Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland.
Publikováno v: British journal of cancer [Br J Cancer] 2021 Mar; Vol. 124 (7), pp. 1249-1259. Date of Electronic Publication: 2021 Jan 21.
Zobrazit plný text záznamu
6
Akademický článek
Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation.
Autor: Li, Pengyun1,2 (AUTHOR), Hu, Xiaotong1,2 (AUTHOR), Fan, Zhiya3 (AUTHOR), Sun, Shiyang1,2 (AUTHOR), Ran, Qijie4,5 (AUTHOR), Wei, Ting1,2 (AUTHOR), Wei, Pengli1,2 (AUTHOR), Jiang, Qiyu4 (AUTHOR), Yan, Jian1,2 (AUTHOR), Yang, Ning1,2 (AUTHOR), Jia, Changkai1,2 (AUTHOR), Yang, Tingting6 (AUTHOR), Mao, Yaqiu1,2 (AUTHOR), Cai, Xu1,2 (AUTHOR), Xu, Tingting1,2 (AUTHOR), Zhao, Zhiyuan1,2 (AUTHOR), Qian, Xiaohong3 (AUTHOR), Qin, Weijie3 (AUTHOR), Zhuang, Xiaomei2 (AUTHOR) xiaomeizhuang@163.com, Fan, Feng4 (AUTHOR) fengfanbio@126.com
Publikováno v: Journal of Hematology & Oncology. 9/2/2024, Vol. 17 Issue 1, p1-30. 30p.
Zobrazit plný text záznamu
7
Akademický článek
Enhanced anti-tumor effects by combination of tucatinib and radiation in HER2-overexpressing human cancer cell lines.
Autor: Amrell, Lukas1 (AUTHOR), Bär, Eric1 (AUTHOR), Glasow, Annegret1,2 (AUTHOR), Kortmann, Rolf-Dieter1 (AUTHOR), Seidel, Clemens1,2 (AUTHOR), Patties, Ina1,2 (AUTHOR) ina.patties@medizin.uni-leipzig.de
Publikováno v: Cancer Cell International. 8/6/2024, Vol. 24 Issue 1, p1-15. 15p.
Zobrazit plný text záznamu
8
Akademický článek
Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017.
Autor: Uitdehaag JCM; Netherlands Translational Research Center B.V., Oss, the Netherlands., Kooijman JJ; Netherlands Translational Research Center B.V., Oss, the Netherlands., de Roos JADM; Netherlands Translational Research Center B.V., Oss, the Netherlands., Prinsen MBW; Netherlands Translational Research Center B.V., Oss, the Netherlands., Dylus J; Netherlands Translational Research Center B.V., Oss, the Netherlands., Willemsen-Seegers N; Netherlands Translational Research Center B.V., Oss, the Netherlands., Kawase Y; Carna Biosciences, Inc., Kobe, Japan., Sawa M; Carna Biosciences, Inc., Kobe, Japan., de Man J; Netherlands Translational Research Center B.V., Oss, the Netherlands., van Gerwen SJC; Netherlands Translational Research Center B.V., Oss, the Netherlands., Buijsman RC; Netherlands Translational Research Center B.V., Oss, the Netherlands., Zaman GJR; Netherlands Translational Research Center B.V., Oss, the Netherlands. guido.zaman@ntrc.nl.
Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2019 Feb; Vol. 18 (2), pp. 470-481. Date of Electronic Publication: 2018 Oct 31.
Zobrazit plný text záznamu
10
Akademický článek
E26 transformation-specific transcription variant 5 in development and cancer: modification, regulation and function.
Autor: Wei, Yi1,2,3 (AUTHOR), Han, Shenqi1,2,3 (AUTHOR), Wen, Jingyuan1,2,3 (AUTHOR), Liao, Jingyu1,2,3 (AUTHOR), Liang, Junnan1,2,3 (AUTHOR), Yu, Jingjing1,2,3 (AUTHOR), Chen, Xiaoping1,2,3,4,5,6 (AUTHOR), Xiang, Shuai1,2,3 (AUTHOR) xiangshuai_hust@163.com, Huang, Zhao1,2,3 (AUTHOR) huangzhao@tjh.tjmu.edu.cn, Zhang, Bixiang1,2,3,4,5,6 (AUTHOR) bixiangzhang@163.com
Publikováno v: Journal of Biomedical Science. 3/6/2023, Vol. 30 Issue 1, p1-22. 22p.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje